跳至主要内容
临床试验/NCT05821582
NCT05821582撤回不适用

Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens

Sanguine Biosciences1 个研究点 分布在 1 个国家开始时间: 2023年3月27日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
Primary Objective- Intestinal side effects of chemotherapy

研究概览

简要总结

The primary objective of the study is to determine whether there is a correlation between the intestinal side effects of chemotherapy treatment and the expression/activity profiles of glucuronidase enzymes in the stool microbiome of the target patient population.

详细描述

STUDY DESIGN:

  • This protocol is a single-center, single-cohort, bioresearch study enrolling up to 8 participants. The cohort is as follows:
  • Cohort 1: Colorectal Cancer: (n=8)
  • The study will enroll participants per the eligibility criteria.
  • Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact (see section 11.0 for details). The biospecimens collected from participants on this study are stool samples.
  • Confirmation of eligibility and medical record review by a member of the study staff will be completed for participants of the disease cohort before they are considered fully enrolled.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Primary Objective- Intestinal side effects of chemotherapy

时间窗: 8 months

The primary objective of the study is to collect stool samples to provide to the sponsor so the sponsor can assess whether there is a correlation between the intestinal side effects of chemotherapy treatment and the expression/activity profiles of glucuronidase enzymes in the stool microbiome of the target patient population.

次要结局

未报告次要终点

研究者

发起方
Sanguine Biosciences
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验